Letters
Hypocalcaemia after intravenous bisphosphonate
BMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7453.1439 (Published 10 June 2004) Cite this as: BMJ 2004;328:1439
Read the product information first
- Shazia Breay, medical manager (Shazia.breay@pharma.novartis.com)
- Oncology Business Unit Novartis Pharmaceuticals UK Limited, Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR
EDITOR—Peter et al describe hypocalcaemia after intravenous bisphosphonate administration.1 Reference to the recommendations given in the summary of product characteristics for the products in question may have abrogated the occurrence of this well known and well documented side effect.
The patient in case 1 had a low adjusted serum calcium concentration before …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £157 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.